Cargando…

Correction: Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes

Detalles Bibliográficos
Autores principales:	McAuliffe, Priscilla F., Evans, Kurt W., Akcakanat, Argun, Chen, Ken, Zheng, Xiaofeng, Zhao, Hao, Eterovic, Agda Karina, Sangai, Takafumi, Holder, Ashley M., Sharma, Chandeshwar, Chen, Huiqin, Do, Kim-Anh, Tarco, Emily, Gagea, Mihai, Naff, Katherine A., Sahin, Aysegul, Multani, Asha S., Black, Dalliah M., Mittendorf, Elizabeth A., Bedrosian, Isabelle, Mills, Gordon B., Gonzalez-Angulo, Ana Maria, Meric-Bernstam, Funda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782992/ https://www.ncbi.nlm.nih.gov/pubmed/26953790 http://dx.doi.org/10.1371/journal.pone.0151121

Ejemplares similares

Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes
por: McAuliffe, Priscilla F., et al.
Publicado: (2015)

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
por: Hassan, Burhan, et al.
Publicado: (2014)

Targeting translation initiation in breast cancer
por: Akcakanat, Argun, et al.
Publicado: (2014)

The rapamycin-regulated gene expression signature determines prognosis for breast cancer
por: Akcakanat, Argun, et al.
Publicado: (2009)

Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer
por: Meric-Bernstam, Funda, et al.
Publicado: (2012)

Epithelial to mesenchymal transition is associated with rapamycin resistance
por: Holder, Ashley M., et al.
Publicado: (2015)

Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation
por: Xing, Yan, et al.
Publicado: (2019)

Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer
por: Woo, S-U, et al.
Publicado: (2017)

ClinSeK: a targeted variant characterization framework for clinical sequencing
por: Zhou, Wanding, et al.
Publicado: (2015)

Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss
por: Owusu-Brackett, Nicci, et al.
Publicado: (2020)

TAK228 enhances antitumor activity of eribulin in triple negative breast cancer
por: Owusu-Brackett, Nicci, et al.
Publicado: (2019)

Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer
por: Arango, Natalia Paez, et al.
Publicado: (2017)

Functional consequence of the MET-T1010I polymorphism in breast cancer
por: Liu, Shuying, et al.
Publicado: (2014)

Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy
por: Caudle, Abigail S, et al.
Publicado: (2012)

Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer
por: Liu, Shuying, et al.
Publicado: (2014)

Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations
por: Pairawan, Seyed, et al.
Publicado: (2022)

Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer
por: Saridogan, Turcin, et al.
Publicado: (2023)

Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy
por: Dominici, Laura S, et al.
Publicado: (2012)

Effectiveness and Safety of Magseed Localization for Excision of Breast Lesions: A Prospective, Phase IV Trial
por: Singh, Puneet, et al.
Publicado: (2020)

RAC1 Alterations Induce Acquired Dabrafenib Resistance in Association with Anaplastic Transformation in a Papillary Thyroid Cancer Patient
por: Bagheri-Yarmand, Rozita, et al.
Publicado: (2021)

Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan
por: Zhao, Ming, et al.
Publicado: (2023)

Whole Genome Sequencing in Cancer Clinics
por: Chen, Ken, et al.
Publicado: (2014)

Personalized cancer therapy—leveraging a knowledge base for clinical decision-making
por: Dumbrava, Ecaterina Ileana, et al.
Publicado: (2018)

First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models
por: Pairawan, Seyed, et al.
Publicado: (2021)

Correction: A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory
por: Arango, Natalia Paez, et al.
Publicado: (2019)

A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory
por: Arango, Natalia Paez, et al.
Publicado: (2017)

Clonal Evolution in Breast Cancer Revealed by Single Nucleus Genome Sequencing
por: Wang, Yong, et al.
Publicado: (2014)

Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis
por: Kono, Miho, et al.
Publicado: (2018)

Prevalence of actionable mutations and copy number alterations and the price of a genomic testing panel
por: Shen, Chan, et al.
Publicado: (2016)

Molecular determinants of post-mastectomy breast cancer recurrence
por: Keene, Kimberly S., et al.
Publicado: (2018)

Efficacy of Quality Criteria to Identify Potentially Harmful Information: A Cross-sectional Survey of Complementary and Alternative Medicine Web Sites
por: Walji, Muhammad, et al.
Publicado: (2004)

Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?
por: Le Du, Fanny, et al.
Publicado: (2015)

FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells
por: Zhao, Ming, et al.
Publicado: (2019)

Correction: FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells
por: Zhao, Ming, et al.
Publicado: (2019)

Reconstructing mutational lineages in breast cancer by multi-patient-targeted single-cell DNA sequencing
por: Leighton, Jake, et al.
Publicado: (2022)

Adapting a Natural Language Processing Tool to Facilitate Clinical Trial Curation for Personalized Cancer Therapy
por: Zeng, Jia, et al.
Publicado: (2014)

Antibody-drug conjugates in lung cancer: dawn of a new era?
por: Coleman, Niamh, et al.
Publicado: (2023)

CanDrA: Cancer-Specific Driver Missense Mutation Annotation with Optimized Features
por: Mao, Yong, et al.
Publicado: (2013)

CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts
por: Huang, Licai, et al.
Publicado: (2022)

Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer
por: Evans, Kurt W., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9hhoa8h5cab1guue3nu4fcvgsi